- NOVARTIS: REMIBRUTINIB MEETS PRIMARY ENDPOINTS IN PHASE 3 TRIALS IN RMS - CUTS RMS RELAPSE RATE BY 35% VERSUS RIVAL - TO SEEK GLOBAL APPROVAL FOR REMIBRUTINIB IN RMS ...
?? Positive AI Sentiment (+6.5 / 10)
Single signal · #175
$NOVN.SW — AI Filing Signal
Public delayed archive entry for this Stock Catalyst AI alert.